The global market for Live Biotherapeutic Products and Microbiome CDMO is anticipated to register significant growth over the forecast period. The market is primarily driven by an expanding pipeline of treatments for various diseases that call for the use of live biotherapeutics, an increase in the number of microbiome-related patents being approved, and rising innovation and technological advancements in the creation of new pharmaceuticals.
The market for live biotherapeutic products and microbiome contract development and manufacturing organisations was severely affected by the COVID-19 pandemic. Globally, clinical trial research has been significantly interrupted. This is particularly relevant given that weaker populations, who are more at risk of COVID-19 exposure, are commonly included in clinical trials. Seres Therapeutics' SER-287 development activities were negatively impacted by the COVID-19 pandemic and the stoppage of non-essential medical procedures at multiple clinical sites.
Based on type, the segment is divided into small molecules, single-strain bacteria, microbial consortiums, genetically modified single-strain bacteria, and others. The small molecule segment dominated the market due to rising pharmaceutical R&D spending, growing need for small molecule medications, and an increase in the prevalence of age- and cancer-related illnesses worldwide.
The North American region is expected to dominate the market over the forecast period. It is characterised by the presence of several established pharmaceutical, biotechnology, and biotherapeutic companies. Additionally, it is projected that rising R&D expenditures by pharmaceutical and life sciences firms will boost the need for contract manufacturing in the area.
The key market players include Arranta Bio, 4D Pharma, Cerbios, BIOSE INDUSTRIE, Assembly Biosciences, Inc., Wacker Chemie AG, Quay Pharmaceuticals, NIZO, Inpac Probiotics, and Lonza. They are utilising a variety of strategies including merger & acquisition, partnership, and expansion. For instance, in November 2021, Lonza announced collaborations with Seres Therapeutics and Bacthera. The main focus of this collaboration is to produce SER-109, Seres' primary pharmaceutical candidate for reoccurring Clostridium difficile infection (rCDI). According to the conditions of the contract, Bacthera will begin commercial production at Lonza's Ibex facility in Switzerland, which is devoted to the manufacturing of LBPs.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.